Ghe LLC Takes $2.37 Million Position in Johnson & Johnson $JNJ

Ghe LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,437 shares of the company’s stock, valued at approximately $2,367,000. Johnson & Johnson makes up approximately 0.8% of Ghe LLC’s investment portfolio, making the stock its 21st biggest position.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after purchasing an additional 3,731,074 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Johnson & Johnson by 3.8% in the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock worth $4,789,914,000 after acquiring an additional 956,239 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 3.5% in the third quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock worth $4,568,313,000 after acquiring an additional 835,146 shares in the last quarter. Legal & General Group Plc boosted its holdings in Johnson & Johnson by 2.8% in the third quarter. Legal & General Group Plc now owns 19,450,064 shares of the company’s stock worth $3,606,431,000 after acquiring an additional 532,790 shares in the last quarter. Finally, Amundi boosted its holdings in Johnson & Johnson by 19.3% in the third quarter. Amundi now owns 13,354,936 shares of the company’s stock worth $2,512,719,000 after acquiring an additional 2,163,838 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 1.7%

JNJ stock opened at $230.37 on Wednesday. Johnson & Johnson has a fifty-two week low of $149.04 and a fifty-two week high of $251.71. The business’s 50-day moving average is $233.64 and its two-hundred day moving average is $224.19. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market cap of $554.55 billion, a price-to-earnings ratio of 26.63, a P/E/G ratio of 2.29 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the prior year, the company earned $2.77 earnings per share. Johnson & Johnson’s revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a $1.34 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is currently 60.12%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J’s DePuy Synthes unit announced an exclusive distribution agreement for the NOVOSIS bone graft substitute in the U.S., Canada and Australia, expanding its orthopedic portfolio and supporting MedTech growth. DePuy Synthes secures exclusive NOVOSIS bone graft distribution partnership (JNJ)
• Positive Sentiment: Multiple bullish articles highlighted J&J as a large-cap pharma stock to own as the industry shows signs of recovery, reinforcing investor confidence in its diversified pharma and MedTech mix. 4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
• Positive Sentiment: Coverage also pointed to J&J’s strong dividend profile and “Dividend King” status, with the company’s long record of dividend growth supporting its appeal to income investors. Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today’s Market
• Neutral Sentiment: Market commentary noted healthcare stocks were a drag on the broader market, which can weigh on J&J even when company-specific news is constructive. Dow Gives Back Early Gains. Healthcare Stocks Are a Drag.
• Negative Sentiment: Fresh talc-litigation headlines remain a key overhang, including a Minnesota jury’s $10.2 million mesothelioma verdict tied to asbestos-contaminated cosmetic talc products. Assessing Johnson & Johnson (JNJ) Valuation After Guidance Raise Growth Initiatives And Talc Litigation Update
• Negative Sentiment: Broader concerns about potential drug-pricing pressure under President Trump could also limit pharma profit expectations, adding policy risk for J&J’s drug business. President Trump’s Drug Pricing Policies Could Hurt Drugmakers’ Profits. Time to Sell Pharma Stocks?

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. Johnson Rice upgraded shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a report on Wednesday, May 13th. HSBC boosted their price objective on shares of Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings downgraded Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a report on Friday, April 24th. Finally, Sanford C. Bernstein upped their price target on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $253.04.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.